Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Pioglitazone (Actos): Empagliflozin has the stronger overall evidence (4.5 vs 4/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Empagliflozin wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Empagliflozin and Pioglitazone (Actos) have evidence — compare verdict strength side-by-side.
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
Off-label metabolic use mirrors diabetes dosing (e.g. 15–45 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (pioglitazone)
Months to years
Months to years
Weeks to months
Throughout use
Weeks to months
Months to years
Months
Throughout use
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
The New England journal of medicine (2016) · Rct · n=3876
IRIS randomized trial in patients with insulin resistance but no diabetes after recent stroke/TIA (n=3,876)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet (London, England) (2005) · Rct · n=5238
PROactive randomized trial in high-cardiovascular-risk type 2 diabetics (n=5,238)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Annals of internal medicine (2016) · Rct
Randomized, placebo-controlled trial of long-term pioglitazone in NASH with prediabetes/type 2 diabetes
Empagliflozin has a higher evidence score (4.5/10 vs 4/10) and wins in 1 of 3 categories.
For support heart health, Empagliflozin has a higher relevance score (72 vs 55).
No known interactions between Empagliflozin and Pioglitazone (Actos) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.